secwatch.observer — SEC 8-K summary
======================================

Issuer:     MEDIFAST INC (MED)
CIK:        0000910329
Form:       8-K
Filed at:   2024-08-05T23:59:59+00:00
Accession:  0001628280-24-034743
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Medifast Q2 revenue falls 43% to $168.6M; net loss $0.75/share, guides Q3 loss
------------------------------------------------------------------------------

- Revenue $168.6M, down 43.1% YoY; active earning Coaches 33,900 (-36.2%); avg revenue per Coach $4,972 (-10.9%).
- GAAP net loss $8.2M ($0.75 loss per diluted share); non-GAAP adjusted net income $10.1M ($0.92 EPS).
- Q3 2024 revenue guidance $125M-$145M; diluted loss per share expected $0.05-$0.70.
- Cash, equivalents and securities $163.5M; no debt; CEO cites transformation and LifeMD collaboration.
- Gross margin improved to 73.2% (non-GAAP 74.8%); SG&A rose to 77.9% of revenue due to fixed-cost deleverage.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/910329/000162828024034743/0001628280-24-034743-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/910329/000162828024034743/med-20240805.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-034743

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer